Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Lancet Pub. Group"" wg kryterium: PB


Tytuł :
India-China border standoff raises concerns on drug supplies.
Autorzy :
Sharma DC
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 15. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
Declines in health insurance among cancer survivors since the 2016 US elections.
Autorzy :
Moss HA; Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: .
Han X; American Cancer Society, Atlanta, GA, USA.
Yabroff KR; American Cancer Society, Atlanta, GA, USA.
Chino J; Division of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Chino F; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 15. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Letter
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Opinia redakcyjna
Tytuł :
Carcinogenicity of opium consumption.
Corporate Authors :
IARC Monographs Vol 126 group
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 08. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Autorzy :
Morschhauser F; Groupe de Recherche sur les formes Injectables et les Technologies Associées, CHU de Lille, Université de Lille, Lille, France. Electronic address: .
Tilly H; Department of Hematology and INSERM U1245, Centre Henri Becquerel and Rouen University, Rouen, France.
Chaidos A; Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, Hammersmith Hospital & Imperial College Healthcare NHS Trust, London, UK.
McKay P; Department of Hematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Phillips T; Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Assouline S; Division of Hematology, Jewish General Hospital, Montreal, QC, Canada; Department of Oncology, McGill University, Montreal, QC, Canada.
Batlevi CL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Campbell P; Department of Clinical Haematology, Barwon Health, University Hospital Geelong, Geelong, VIC, Australia.
Ribrag V; Hematology Department, Gustave Roussy, Villejuif, France.
Damaj GL; Hematology Institute, Hematologie Clinique, University Hospital School of Medicine, Caen, France.
Dickinson M; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Jurczak W; Department of Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Kazmierczak M; Department of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Opat S; Haematology Department, Monash University, Melbourne, VIC, Australia.
Radford J; Department of Medical Oncology, University of Manchester, Manchester, UK; NIHR Manchester Clinical Research Facility, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK.
Schmitt A; Department of Hematology, Institut Bergonié, Bordeaux, France.
Yang J; Clinical Development, Epizyme, Cambridge, MA, USA.
Whalen J; Clinical Development, Epizyme, Cambridge, MA, USA.
Agarwal S; Clinical Development, Epizyme, Cambridge, MA, USA.
Adib D; Clinical Development, Epizyme, Cambridge, MA, USA.
Salles G; Department of Hematology, Lyon-Sud Hospital, University of Lyon, Pierre-Bénite, France.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 06. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
EZH2 inhibition for epithelioid sarcoma and follicular lymphoma.
Autorzy :
Groisberg R; Department of Melanoma and Sarcoma Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 06. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Autorzy :
Gounder M; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: .
Schöffski P; Department of General Medical Oncology, and Laboratory of Experimental Oncology, University Hospitals Leuven, KU Leuven, Leuven Cancer Institute, Leuven, Belgium.
Jones RL; Royal Marsden Hospital and Institute of Cancer Research, London, UK.
Agulnik M; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Cote GM; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Villalobos VM; Anschutz Medical Campus, University of Colorado Denver, Aurora, CO, USA; Janssen Pharmaceuticals, Spring House, PA, USA.
Attia S; Mayo Clinic, Jacksonville, FL, USA.
Chugh R; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Chen TW; National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Jahan T; University of California San Francisco, San Francisco, CA, USA.
Loggers ET; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gupta A; The Hospital for Sick Children and Princess Margaret Cancer Center, Toronto, ON, Canada.
Italiano A; Institut Bergonie and University of Bordeaux, Bordeaux, France.
Demetri GD; Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA.
Ratan R; MD Anderson Cancer Center, Houston, TX, USA.
Davis LE; Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
Mir O; Gustave Roussy Cancer Institute, Paris, France.
Dileo P; University College London Hospitals NHS Foundation Trust, London, UK.
Van Tine BA; School of Medicine, Washington University in St Louis, St Louis, MO, USA.
Pressey JG; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Lingaraj T; Epizyme, Cambridge, MA, USA.
Rajarethinam A; Epizyme, Cambridge, MA, USA.
Sierra L; Epizyme, Cambridge, MA, USA; Bristol Myers Squibb, Cambridge, MA, USA.
Agarwal S; Epizyme, Cambridge, MA, USA.
Stacchiotti S; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 06. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
A roadmap for the early detection and diagnosis of cancer.
Autorzy :
Crosby D; Cancer Research UK, London E20 1JQ, UK. Electronic address: .
Lyons N; Cancer Research UK, London E20 1JQ, UK.
Greenwood E; Cancer Research UK, London E20 1JQ, UK.
Harrison S; Cancer Research UK, London E20 1JQ, UK.
Hiom S; Cancer Research UK, London E20 1JQ, UK.
Moffat J; Cancer Research UK, London E20 1JQ, UK.
Quallo T; Cancer Research UK, London E20 1JQ, UK.
Samuel E; Cancer Research UK, London E20 1JQ, UK.
Walker I; Cancer Research UK, London E20 1JQ, UK.
Pokaż więcej
Corporate Authors :
Early Detection and Diagnosis Roadmap Steering Group
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 05. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series.
Autorzy :
Matschke J; Institute of Neuropathology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Lütgehetmann M; Institute of Medical Microbiology, Virology, and Hygiene, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany; Center for Infection Research, Partner Site Hamburg-Borstel-Lübeck-Riems, Germany.
Hagel C; Institute of Neuropathology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Sperhake JP; Institute of Legal Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Schröder AS; Institute of Legal Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Edler C; Institute of Legal Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Mushumba H; Institute of Legal Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Fitzek A; Institute of Legal Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Allweiss L; I Department of Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Dandri M; I Department of Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany; Center for Infection Research, Partner Site Hamburg-Borstel-Lübeck-Riems, Germany.
Dottermusch M; Institute of Neuropathology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Heinemann A; Institute of Legal Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Pfefferle S; Institute of Medical Microbiology, Virology, and Hygiene, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Schwabenland M; Institute of Neuropathology, University of Freiburg, Freiburg, Germany.
Sumner Magruder D; Institute of Medical Systems Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Bonn S; Institute of Medical Systems Biology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.
Prinz M; Institute of Neuropathology, University of Freiburg, Freiburg, Germany; Center for Basics in Neuromodulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Signaling Research Centers BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Gerloff C; Department of Neurology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Püschel K; Institute of Legal Medicine, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Krasemann S; Institute of Neuropathology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Aepfelbacher M; Institute of Medical Microbiology, Virology, and Hygiene, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
Glatzel M; Institute of Neuropathology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Neurology [Lancet Neurol] 2020 Oct 05. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
Catch me if you can: SARS-CoV-2 detection in brains of deceased patients with COVID-19.
Autorzy :
Frank S; Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, CH-4031 Basel, Switzerland. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Neurology [Lancet Neurol] 2020 Oct 05. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
New empowerment tool for all patients with cancer in Europe.
Autorzy :
Gourd E
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 01. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
Tobacco Transformation Index under fire.
Autorzy :
Burki TK
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct 01. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Czasopismo naukowe
Tytuł :
Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study.
Autorzy :
Jin G; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China.
Lv J; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
Yang M; Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Wang M; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhu M; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China.
Wang T; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Yan C; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China.
Yu C; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
Ding Y; Department of Gastroenterology, the Affiliated Hospital of Yangzhou University, Yangzhou, China.
Li G; Department of General Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Ren C; Department of Laboratory Medicine, Clinical Medical College of Yangzhou University, Yangzhou, China.
Ni J; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Zhang R; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
Guo Y; Chinese Academy of Medical Sciences, Beijing, China.
Bian Z; Chinese Academy of Medical Sciences, Beijing, China.
Zheng Y; Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Zhang N; Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jiang Y; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China.
Chen J; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China.
Wang Y; Department of Gastric Cancer, Shanghai Medical College, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Xu D; Department of Gastric Cancer, Shanghai Medical College, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Zheng H; Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Yang L; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Chen Y; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Walters R; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Millwood IY; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Dai J; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China.
Ma H; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China.
Chen K; Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Chen Z; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Hu Z; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China.
Wei Q; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Shen H; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China. Electronic address: .
Li L; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1378-1386.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: In Process; MEDLINE
Czasopismo naukowe
Tytuł :
Ethical concerns regarding private equity in Right to Try in the USA.
Autorzy :
Lee SW; Ethics Program, Wellstar Health System, Atlanta, GA 30339, USA. Electronic address: .
Hurst DJ; Department of Family Medicine, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1260-1262.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: In Process; MEDLINE
Czasopismo naukowe
Tytuł :
Oncology training in Latin America: are we ready for 2040?
Autorzy :
Duma N; Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin, Madison, WI, USA.
Moraes FY; Department of Oncology, Division of Radiation Oncology, Queen's University, Kingston K7L 5P9, ON, Canada. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1267-1268.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: In Process; MEDLINE
Czasopismo naukowe
Tytuł :
Will cancer care be a winner in the US election?
Autorzy :
The Lancet Oncology
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1253.
Typ publikacji :
Editorial
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: In Process; MEDLINE
Opinia redakcyjna
Tytuł :
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Autorzy :
Sargos P; Institut Bergonié, Bordeaux, France. Electronic address: .
Chabaud S; Centre Léon Bérard, Lyon, France.
Latorzeff I; Clinique Pasteur, Toulouse, France.
Magné N; Institut de Cancérologie de la Loire, Saint-Priest-en-Jarèz, France.
Benyoucef A; Centre Henri Becquerel, Rouen, France.
Supiot S; Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain, France.
Pasquier D; Centre Oscar Lambret and Lille University, Lille, France.
Abdiche MS; Centre Hospitalier Robert Boulin, Libourne, France.
Gilliot O; Clinique Marzet, Pau, France.
Graff-Cailleaud P; Institut Claudius Regaud, Toulouse, France.
Silva M; Centre François Baclesse, Caen, France.
Bergerot P; Clinique Mutualiste de l'Estuaire, Cité Sanitaire, Saint-Nazaire, France.
Baumann P; Centre d'Oncologie de Gentilly, Nancy, France.
Belkacemi Y; Hôpitaux Universitaires Henri Mondor, Université Paris Est Créteil, Creteil, France.
Azria D; Institut Régional du Cancer de Montpellier Val d'Aurelle, Montpellier, France.
Brihoum M; Unicancer, Paris, France.
Soulié M; CHU de Toulouse, Toulouse, France.
Richaud P; Institut Bergonié, Bordeaux, France.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1341-1352.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: In Process; MEDLINE
Czasopismo naukowe
Tytuł :
Correction to Lancet Oncol 2020; 21: 796-807.
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. e462.
Typ publikacji :
Published Erratum
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 Subsets: PubMed not MEDLINE; MEDLINE
Tytuł :
Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia.
Autorzy :
Wong JYC; Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Filippi AR; Department of Radiation Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy. Electronic address: .
Scorsetti M; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Hospital-IRCCS, Rozzano, Milan, Italy.
Hui S; Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Muren LP; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus N, Denmark.
Mancosu P; Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Hospital-IRCCS, Rozzano, Milan, Italy.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. e477-e487.
Typ publikacji :
Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: In Process; MEDLINE
Czasopismo naukowe
Tytuł :
Demystifying the estimand framework: a case study using patient-reported outcomes in oncology.
Autorzy :
Fiero MH; Office of Biostatistics, US Food and Drug Administration, Silver Spring, MD, USA. Electronic address: .
Pe M; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Weinstock C; Office of Oncologic Diseases, US Food and Drug Administration, Silver Spring, MD, USA.
King-Kallimanis BL; Center for Drug Evaluation and Research and Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Komo S; Office of Biostatistics, US Food and Drug Administration, Silver Spring, MD, USA.
Klepin HD; Wake Forest School of Medicine, Winston-Salem, NC, USA.
Gray SW; City of Hope, Duarte, CA, USA.
Bottomley A; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Kluetz PG; Center for Drug Evaluation and Research and Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Sridhara R; Office of Biostatistics, US Food and Drug Administration, Silver Spring, MD, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. e488-e494.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: In Process; MEDLINE
Czasopismo naukowe
Tytuł :
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Autorzy :
Emens LA; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: .
Esteva FJ; Perlmutter Cancer Center at New York University Langone Health, New York, NY, USA.
Beresford M; Royal United Hospital, Bath, UK.
Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
De Laurentiis M; Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy.
Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Wang Y; Roche (China) Holding, Shanghai, China.
Salgado R; Department of Pathology, Gasthuis Zusters Antwerpen-Ziekenhuis Netwerk Antwerpen Hospitals, Antwerp, Belgium.
Mani A; Genentech, South San Francisco, CA, USA.
Shah J; Genentech, South San Francisco, CA, USA.
Lambertini C; F Hoffmann-La Roche, Basel, Switzerland.
Liu H; Genentech, South San Francisco, CA, USA.
de Haas SL; F Hoffmann-La Roche, Basel, Switzerland.
Patre M; F Hoffmann-La Roche, Basel, Switzerland.
Loi S; Division of Research, Peter MacCallum Cancer Center, Melbourne, VIC, Australia. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1283-1295.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: In Process; MEDLINE
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies